Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents.

de Vries, I Jolanda M;Castelli, Chiara;Huygens, Caroline;Jacobs, Joannes F M;Lucas, Sophie;et.al.
(2011) Clinical Cancer Research — Vol. 17, n° 4, p. 841-848 (2011)

Files

DEVRIES_CCR2011.pdf
  • Restricted Access
  • Adobe PDF
  • 400.38 KB
Request a copy

Details

Authors
Show more
Abstract
Regulatory T cells (Tregs) are thought to inhibit antitumor immune responses, and their depletion could therefore have a synergistic effect with therapeutic cancer vaccines. We investigated the impact of three medications on blood Treg frequency in vaccinated cancer patients.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

de Vries, I. J. M., Castelli, C., Huygens, C., Jacobs, J. F. M., Stockis, J., Schuler-Thurner, B., Adema, G. J., Punt, C. J. A., Rivoltini, L., Schuler, G., Coulie, P., & Lucas, S. (2011). Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents. Clinical Cancer Research, 17(4), 841-848. https://doi.org/10.1158/1078-0432.CCR-10-2227 (Original work published 2011)